Oncolytics Biotech (US:ONCY) Prnewswireยท2024-05-23 15:51Core Insights - The article discusses advancements in pancreatic cancer research and treatment, highlighting the importance of early detection and innovative therapies being developed by various biotech companies [1][2][3]. Group 1: Pancreatic Cancer Statistics and Research - Pancreatic cancer is one of the deadliest cancers, with up to 80% of patients diagnosed at late stages, making early detection crucial [1]. - The American Cancer Society estimates that approximately 66,440 individuals in the USA will be diagnosed with pancreatic cancer in 2024, with about 51,750 expected to die from the disease [1]. Group 2: Oncolytics Biotech Inc. Developments - Oncolytics Biotech's pelareorep has received Fast Track Designation from the FDA for pancreatic cancer treatment and is collaborating with the Global Coalition for Adaptive Research (GCAR) to evaluate its use as a first-line treatment for metastatic pancreatic ductal adenocarcinoma [2][3]. - The company is advancing research on pelareorep combined with modified FOLFIRINOX (mFOLFIRINOX) and Tecentriq, with a new study cohort cleared for patient enrollment [3][5]. Group 3: Other Biotech Companies and Innovations - Candel Therapeutics received FDA orphan drug designation for its CAN-2409 treatment in pancreatic cancer, which combines a specially engineered virus with valacyclovir to enhance immune response against tumors [6][8]. - AstraZeneca's drug Enhertu has received accelerated approval for treatment across multiple HER2-expressing solid tumors, including pancreatic cancer [9][10]. - Merus N.V. announced the FDA's acceptance of a Biologics License Application for zenocutuzumab, targeting NRG1+ pancreatic cancer, which may offer a substantial improvement over existing therapies [10][11]. - Lantern Pharma is collaborating with Oregon Therapeutics to optimize the development of XCE853, a first-in-class drug candidate for various cancers, including drug-resistant pancreatic cancer [12][13].